| Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity LC Tsoi, SL Spain, J Knight, E Ellinghaus, PE Stuart, F Capon, J Ding, ... Nature genetics 44 (12), 1341-1348, 2012 | 1050 | 2012 |
| Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis CEM Griffiths, BE Strober, P Van De Kerkhof, V Ho, R Fidelus-Gort, ... New England Journal of Medicine 362 (2), 118-128, 2010 | 1033 | 2010 |
| European S3-guidelines on the systemic treatment of psoriasis vulgaris D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, ... Journal of the European Academy of Dermatology and Venereology 23 (SUPPL. 2 …, 2009 | 960 | 2009 |
| Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions BB Davidovici, N Sattar, PC Jörg, L Puig, P Emery, JN Barker, ... Journal of Investigative Dermatology 130 (7), 1785-1796, 2010 | 873 | 2010 |
| Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof, C Paul, A Menter, ... The Lancet 386 (9993), 541-551, 2015 | 867 | 2015 |
| A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ... British Journal of Dermatology 152 (6), 1304-1312, 2005 | 860 | 2005 |
| Psoriasis is associated with increased β-defensin genomic copy number EJ Hollox, U Huffmeier, PLJM Zeeuwen, R Palla, J Lascorz, ... Nature genetics 40 (1), 23-25, 2008 | 817 | 2008 |
| Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey MG Lebwohl, H Bachelez, J Barker, G Girolomoni, A Kavanaugh, ... Journal of the American Academy of Dermatology 70 (5), 871-881. e30, 2014 | 566 | 2014 |
| European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC A Nast, P Gisondi, AD Ormerod, P Saiag, CH Smith, PI Spuls, ... Journal of the European Academy of Dermatology and Venereology 29 (12), 2277 …, 2015 | 535 | 2015 |
| Leg ulcers: a review of their impact on daily life A Persoon, MM Heinen, CJM Van Der Vleuten, MJ De Rooij, ... Journal of Clinical Nursing 13 (3), 341-354, 2004 | 504 | 2004 |
| Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin HJ Bovenschen, PC Van De Kerkhof, PE Van Erp, R Woestenenk, ... Journal of Investigative Dermatology 131 (9), 1853-1860, 2011 | 493 | 2011 |
| European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey L Dubertret, U Mrowietz, A Ranki, PCM Van De Kerkhof, S Chimenti, ... British Journal of Dermatology 155 (4), 729-736, 2006 | 473 | 2006 |
| Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris K Kragballe, BT Gjertsen, D De Hoop, PCM Van de Kerkhof, T Karlsmark, ... The Lancet 337 (8735), 193-196, 1991 | 430 | 1991 |
| Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial H Bachelez, PCM Van De Kerkhof, R Strohal, A Kubanov, F Valenzuela, ... The Lancet 386 (9993), 552-561, 2015 | 428 | 2015 |
| European consensus statement on phenotypes of pustular psoriasis AA Navarini, AD Burden, F Capon, U Mrowietz, L Puig, S Köks, K Kingo, ... Journal of the European Academy of Dermatology and Venereology 31 (11), 1792 …, 2017 | 418 | 2017 |
| Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients E De Jong, B Seegers, MK Gulinck, JBM Boezeman, PCM Van de Kerkhof Dermatology 193 (4), 300-303, 1996 | 391 | 1996 |
| High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis GJ de Jongh, PLJM Zeeuwen, M Kucharekova, R Pfundt, PG van der Valk, ... Journal of investigative dermatology 125 (6), 1163-1173, 2005 | 360 | 2005 |
| Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis PCM van de Kerkhof, CEM Griffiths, K Reich, CL Leonardi, A Blauvelt, ... Journal of the American Academy of Dermatology 75 (1), 83-98. e4, 2016 | 331 | 2016 |
| Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study M Flendrie, WHPM Vissers, MCW Creemers, EMGJ de Jong, ... Arthritis research & therapy 7, 1-11, 2005 | 319 | 2005 |
| High prevalence of foot diseases in Europe: results of the Achilles Project T Burzykowski, G Molenberghs, D Abeck, E Haneke, R Hay, A Katsambas, ... Mycoses 46 (11‐12), 496-505, 2003 | 310 | 2003 |
